RAPT Therapeutics Reports First Quarter 2023 Financial Results
Company maintains strong cash position of $231.6 millionSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
Cancer
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins...
Prime Medicine Reports First Quarter 2023 Financial Results and Provides Business Updates
-- New data further demonstrating ability of Prime Editing to correct causative mutation of CGD and highlighting potential of PASSIGE...
Morphic Presents New Biomarker Data at DDW 2023 Supporting MORF-057 Program in Ulcerative Colitis
-Data demonstrate increases in circulating plasmablasts, consistent with the increased antibody activity expected with anti-inflammatory mechanism of A4B7 inhibition-WALTHAM, Mass.,...
Onconova Therapeutics Doses First Patient in Phase 1/2a Trial of Narazaciclib Combined with Letrozole in Endometrial Cancer
Prior data provide clinical proof-of-concept for narazaciclib’s mechanism of action in endometrial cancer Preliminary data from trial’s Phase 1 portion...
Salarius Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides a Business Update
FDA removes partial clinical hold on seclidemstat Phase 1/2 trial in Ewing sarcoma; Salarius plans to meet with FDA to...
MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results
agenT-797, an allo-iNKT cell therapy, shows clinical responses in heavily pre-treated solid tumor cancers when administered with anti-PD-1 and persists...
Candel Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage...
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
98.9% of patients treated with Xoft remained recurrence-free at a median follow-up of 7.6 years, according to recent study published...
Interoperability, access and public-private collaboration were the most discussed topics at the Italy Healthcare Innovation Summit in Milan Italian
MILAN, Italy, May 11, 2023 (GLOBE NEWSWIRE) -- The Italy Healthcare Innovation Summit, an event organized by Bamberg Health, attracted...
Celularity Announces Advisory Guidance From Tamer Group Regarding Anticipated 2023 Purchase Orders for Celularity Branded Halal-Certified Biomaterial Products
Celularity has been advised by the Tamer Group to expect at least $60 million to $80 million in 2023 purchase...
SomaLogic expands into China with groundbreaking Biostar Technology Limited Partnership
SomaLogic to deliver 7,000-plex SomaScan® Platform to researchers in attractive Chinese proteomics marketSHANGHAI and BOULDER, Colo., May 10, 2023 (GLOBE...
Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohn’s Disease
Collaboration Brings Together TScan’s Proprietary Target Discovery Platform and Amgen’s Inflammation Therapeutic Expertise and Research Capabilities TScan to Receive $30...
Outpace Bio, a Leader in Protein Design for Cell Therapy, Announces Presentation at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Seattle, WA, May 09, 2023 (GLOBE NEWSWIRE) -- Outpace Bio, a company using protein design and cell engineering to create...
AIM ImmunoTech to Discuss First Quarter 2023 Financial Results on May 16, 2023 and Host Conference Call and Webcast
OCALA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), an immuno-pharma company...
Catalyst Pharmaceuticals Advances sNDA Submission Plans To Increase Indicated Maximum Dose For FIRDAPSE® From 80 mg Per Day To 100 mg Per Day
Concluded Positive FDA Type-C Meeting in Early May 2023 Company On Track to Submit an sNDA Early in the Third...
ORYZON to Give Updates on Corporate Progress in May-June
BioEquity Europe 2023Foro Medcap BME 2023 VI Ibero-American Congress CEAPI 2023BIO International Conference 2023Jefferies Healthcare Conference 2023MidCap Paris 2023MADRID and...
FDA Removes Partial Clinical Hold on Salarius Pharmaceuticals’ Phase 1/2 Clinical Trial with Seclidemstat in Patients with Ewing Sarcoma
Decision Follows Review of Comprehensive Safety Data Package Submitted by the Company Salarius Plans to Meet with FDA to Discuss...
Immutep to Participate in the JMP Securities Life Sciences Conference
Media Release SYDNEY, AUSTRALIA, May 09, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”),...
Replimune to Participate in the Piper Sandler Spring Biopharma Symposium
WOBURN, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the...